Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis

Kizhakkedath,Reji

doi:10.3892/mmr.2013.1661

Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis

Authors:
- Reji Kizhakkedath
View Affiliations

Affiliations: Anugraha Medical Centre, Kakkanad, Kochi, Kerala 682030, India
Published online on: August 29, 2013 https://doi.org/10.3892/mmr.2013.1661
Pages: 1542-1548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A formulation containing Curcuma longa and Boswellia serrata extracts (CB formulation) was evaluated for safety and efficacy in osteoarthritic patients and directly compared with the selective COX-2 inhibitor, celecoxib. In total, 54 subjects were screened, 30 subjects were enrolled and 28 completed the study. The treatment was well tolerated and did not produce any adverse effect in patients, as judged by the vital signs, hemogram, liver and renal function tests. The CB formulation at 500 mg administered twice a day, was more successful than administering celecoxib 100 mg twice a day for symptom scoring and clinical examination. The formulation was found to be safe and no dose-related toxicity was found.

View Figures

View References

1	Dillion CF, Hirsch R, Rasch EK and Gu Q: Symptomatic hand osteoarthritis in the United States: prevalence and functional impairment estimates from the third U.S. National Health and Nutrition Examination Survey 1991–1994. Am J Phys Med Rehabil. 86:12–21. 2007.PubMed/NCBI
2	Fautrel B, Hilliquin P, Rozenberg S, et al: Impact of osteoarthritis: results of nationwide survey of 10,000 patients consulting for OA. Joint Bone Spine. 72:235–240. 2005. View Article : Google Scholar : PubMed/NCBI
3	Rabenda V, Manette C, Lemmens R, et al: Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol. 33:1152–1158. 2006.PubMed/NCBI
4	Gabriel SE, Crowson CS, Campion ME and O'Fallon WM: Direct medical costs unique to people with arthritis. J Rheumatol. 24:719–725. 1997.PubMed/NCBI
5	Gupta S, Hawker GA, Laporte A, Croxford R and Coyte PC: The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology (Oxford). 44:1531–1537. 2005. View Article : Google Scholar : PubMed/NCBI
6	Le Pen C, Reygrobellet C and Gérentes I: Financial costs of osteoarthritis in France. The ‘COART’ France study Joint Bone. Spine. 72:567–570. 2005.
7	Zhang W, Moskowitz RW, Nuki G, et al: OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 15:981–1000. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zhang W, Moskowitz RW, Nuki G, et al: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 16:137–162. 2008. View Article : Google Scholar
9	Zhang W, Doherty M, Arden N, et al: EULAR evidence-based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 64:669–681. 2005. View Article : Google Scholar
10	Zhang W, Doherty M, Leeb BF, et al: EULAR evidence-based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 66:377–388. 2007. View Article : Google Scholar
11	Jordan KM, Arden NK, Doherty M, et al: EULAR Recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 62:1145–1155. 2003. View Article : Google Scholar
12	Pincus T, Koch GG, Sokka T, et al: A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 44:1587–1598. 2001. View Article : Google Scholar : PubMed/NCBI
13	Case JP, Baliunas AJ and Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med. 163:169–178. 2003. View Article : Google Scholar : PubMed/NCBI
14	Gupta I, Gupta V, Parihar A, et al: Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 3:511–514. 1998.PubMed/NCBI
15	Sander O, Herborn G and Rau R: Is H15 (resin extract of Boswellia serrata, ‘incense’) a useful supplement to establish drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol. 57:11–16. 1998.(In German).
16	Gerhardt H, Seifert F, Buvari P, et al: Therapy of active Crohn disease with Boswellia serrata extract H15. Z Gastroenterol. 39:11–17. 2001.(In German).
17	Kimmatkar N, Thawani V, Hingorani L and Khiyani R: Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee - a randomized, double-blind, placebo-controlled trial. Phytomedicine. 10:3–7. 2003. View Article : Google Scholar : PubMed/NCBI
18	Sontakke S, Thawani V, Pimpalkhute P, et al: Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of the knee. Indian J Pharmacol. 39:27–29. 2007. View Article : Google Scholar
19	Sengupta K, Alluri KV, Satish AR, et al: A double-blind, randomized, placebo-controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 10:R852008. View Article : Google Scholar : PubMed/NCBI
20	Madisch A, Miehlke S, Eichele O, et al: Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 22:1445–1451. 2007. View Article : Google Scholar : PubMed/NCBI
21	Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR and Ammon HP: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 261:1143–1146. 1992.PubMed/NCBI
22	Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HP and Safayhi H: Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 117:615–618. 1996. View Article : Google Scholar : PubMed/NCBI
23	Sailer ER, Schweizer S, Boden SE, Ammon HP and Safayhi H: Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem. 256:364–368. 1998. View Article : Google Scholar : PubMed/NCBI
24	Liu JJ, Nilsson A, Oredsson S, Badmaev V, Zhao WZ and Duan RD: Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis. 23:2087–2093. 2002. View Article : Google Scholar : PubMed/NCBI
25	Shoba G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS: Influence of piperine in pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64:353–356. 1998. View Article : Google Scholar : PubMed/NCBI
26	Schweizer S, von Brocke AF, Boden SE, Bayer E, Ammon HP and Safayhi H: Workup-dependent formation of 5-lipoxygenase-inhibitory boswellic acid analogues. J Nat Prod. 63:1058–1061. 2000. View Article : Google Scholar : PubMed/NCBI